TissueGene rakes in W202bn from 300x subscribed IPO
Pharmaceutical firm TissueGene has raised W202.5bn ($178.9m) after pricing its IPO on South Korea’s second board at the top of guidance, according to a banker close to the deal.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: